Difference between revisions of "deLemus"
| Line 18: | Line 18: | ||
<big>Here are the recently confirmed leading mutations.</big> | <big>Here are the recently confirmed leading mutations.</big> | ||
<!--2-column table--> | <!--2-column table--> | ||
| + | |||
| + | <html> | ||
| + | <style> | ||
| + | .molstar { | ||
| + | position: relative; | ||
| + | width: 100%; | ||
| + | padding-bottom: 56.25%; | ||
| + | } | ||
| + | </style> | ||
| + | <link rel="stylesheet" type="text/css" href="https://molstar.org/viewer/molstar.css" /> | ||
| + | <script type="text/javascript" src="https://molstar.org/viewer/molstar.js"></script> | ||
| + | |||
| + | <div id="viewer-1" class="molstar" style="padding-bottom: 40%;"></div> | ||
| + | <script type="text/javascript"> | ||
| + | molstar.Viewer.create('viewer-1', { | ||
| + | layoutIsExpanded: false, | ||
| + | layoutShowControls: false, | ||
| + | layoutShowRemoteState: false, | ||
| + | layoutShowSequence: true, | ||
| + | layoutShowLog: false, | ||
| + | layoutShowLeftPanel: true, | ||
| + | |||
| + | viewportShowExpand: true, | ||
| + | viewportShowSelectionMode: false, | ||
| + | viewportShowAnimation: false, | ||
| + | }).then(viewer => { | ||
| + | viewer.loadSnapshotFromUrl('https://wiki.laviebay.hkust.edu.hk/deLemus/RESEARCH_TEAMS/pdb/LM_latest.molx', 'molx'); | ||
| + | }); | ||
| + | </script> | ||
| + | </html> | ||
===2023.01.31=== | ===2023.01.31=== | ||
| Line 177: | Line 207: | ||
<script type="text/javascript" src="https://counter10.optistats.ovh/private/counter.js?c=9pt5d2hy2d328lsrbbs6nlkm4sax62ug&down=async" async></script> | <script type="text/javascript" src="https://counter10.optistats.ovh/private/counter.js?c=9pt5d2hy2d328lsrbbs6nlkm4sax62ug&down=async" async></script> | ||
<noscript><a href="https://www.freecounterstat.com" title="free website counter"><img src="https://counter10.optistats.ovh/private/freecounterstat.php?c=9pt5d2hy2d328lsrbbs6nlkm4sax62ug" border="0" title="free website counter" alt="free website counter"></a></noscript> | <noscript><a href="https://www.freecounterstat.com" title="free website counter"><img src="https://counter10.optistats.ovh/private/freecounterstat.php?c=9pt5d2hy2d328lsrbbs6nlkm4sax62ug" border="0" title="free website counter" alt="free website counter"></a></noscript> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
</html> | </html> | ||
Revision as of 23:32, 8 February 2023
Dynamic Expedition of Leading Mutations in SARS-CoV-2 Spike Glycoprotein
The dynamic epidemiology of coronavirus disease 2019 (COVID-19) since its outbreak has been a result of the continuous evolution of its etiological agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within the first 2 years of this pandemic, the World Health Organization (WHO) has already announced 4 variants of concern (VOC), namely alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2), together with numerous variants of interest (VOI). The latest lineage to be designated a VOC would be omicron (B.1.1.529),[1] from which a diverse variant soup is generated.[2] From the original BA.1 strain of November 2021 to the most recent XBB and BQ.1 strains of late 2022,[3][4] each omicron subvariant has successively proliferated and outcompeted its once dominant antecedent.[5] The emergence of all these variants has brought along many novel mutations that continue to fine-tune the fitness of the virus,[6][7] leading to its persistent global circulation. Recent emerging variant (EV) data retrieved from GISAID, as of 17 January 2023, has revealed that the top 4 most rapidly spreading lineages are the BA.1.1.22, CH.1.1, XBB.1.5, and BQ.1.1 variants, among which XBB.1.5 has been found to be especially prevalent in the US,[8] making up of more than 40% of its sequence coverage in early January 2023.
Spike Glycoprotein
The spike glycoprotein of SARS-CoV-2 is a trimeric type I viral fusion protein that binds the virus to the angiotensin-converting enzyme 2 (ACE2) receptor of a host cell.[9] It is composed of 2 subunits: the N-terminal subunit 1 (S1) and C-terminal subunit 2 (S2), within which multiple domains lie. The S1 region facilitates ACE2 binding and is made up of an N-terminal domain (NTD ~ 1 – 325), a receptor-binding domain (RBD ~ 326 – 525), and 2 C-terminal subdomains (CTD1 and CTD2 ~ 526 – 688), while the downstream S2 region is responsible for mediating virus-host cell membrane fusion.
Update (03/02/2023)
The identified leading mutations are listed as follows [10]:
Here are the recently confirmed leading mutations.
2023.01.31
| Outlined Mutations | Confirmed in VOC/Emerging Variants |
|---|---|
| V445A | BQ.1.1 |
| T883I | BQ.1.1 |
2023.01.17 - 2023.01.25
| Outlined Mutations | Confirmed in VOC/Emerging Variants |
|---|---|
| H146-/K | BQ.1.1, XBB.1.5 |
| F486A | BQ.1.1 |
| E583D | BQ.1.1 |
| Q613H | BQ.1.1 |
| S939F | BQ.1.1 |
Summary
References
- ↑ Karim, S. S. A. & Karim, Q. A. Omicron SARS-CoV-2 variant: A new chapter in the COVID-19 pandemic. Lancet 398, 2126 (2021).
- ↑ Callaway, E. COVID ‘variant soup’ is making winter surges hard to predict. Nature 611, 213 (2022).
- ↑ Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279 (2023).
- ↑ Qu, P. et al. Enhanced Neutralization Resistance of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe 31, 9 (2023)
- ↑ Del Rio, C. & Malani, P. N. COVID-19 in 2022 - The Beginning of the End or the End of the Beginning? JAMA 327, 2389 (2022).
- ↑ Carabelli, A. M. et al. SARS-CoV-2 variant biology: Immune escape, transmission and fitness. Nat Rev Microbiol (2023).
- ↑ Witte, L. et al. Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape. Nat Commun 14, 302 (2023).
- ↑ Callaway, E. Coronavirus variant XBB.1.5 rises in the United States — is it a global threat? Nature 613, 222 (2023).
- ↑ Jackson, C. B., Farzan, M., Chen, B. & Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 23, 3 (2021).
- ↑ deLemus team, Analysis of Leading Mutations in SARS-CoV-2 Spike Glycoproteins (in preparation, 2023).
